Discovery of New Gene Provides Opportunity for Development of New Drugs and Prenatal Screening for Dystonia

New York, NY (PRWEB) December 18, 2012

The findings, published online December 9 in Nature Genetics, provide novel insights into the genetic basis underlying PTD. The research study was led by Laurie Ozelius, PhD, Associate Professor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. The discovery identifies the human G olf (GNAL) gene, the first PTD gene that directly points to the dopamine signal transduction system as the origin of pathophysiology. Exome sequencing of patients in two families with dystonia revealed mutations in GNAL. Further screening of 39 other families with a history of PTD identified another six mutations in this gene. The research provides the potential opportunity for developing new treatments, and prenatal screening tests.

Dystonia is a movement disorder characterized by repetitive twisting muscle contractions and postures that can affect the face, neck, arms, legs, or torso. Common symptoms include tremors, voice problems, or a dragging foot. The molecular pathophysiology of the disease is poorly understood, in part due to limited knowledge of the genetic basis of the disorder. The disease is most often inherited in an autosomal-dominant manner, with reduced penetrance ranging between 15-60 percent for different forms of PTD. With more than nine loci mapped for PTD, only three genes have been previously identified.

The successful application of exome sequencing for the identification of the GNAL gene proves that this is a powerful and efficient tool which will rapidly accelerate the pace of dystonia gene discovery and consequently, our understanding of the pathways involved in PTD, said Laurie Ozelius, PhD, Associate Professor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. Any new gene offers the potential to develop new therapeutics, but because GNAL belongs to a well-studied signal transduction pathway, other components in this pathway may also be targets for drug development, said Tania Fuchs, PhD, Instructor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, who is first author of the paper.

This research was funded in part by the Dystonia Medical Research Foundation, the Bachmann-Strauss Dystonia & Parkinson Foundation, and the National Institute of Health (NIH).

Art Kessler, President of the Dystonia Medical Research Foundation, said, We are delighted that we were able to support this research into the underlying genetic basis of dystonia. While not widely known, dystonia affects more people than muscular dystrophy, Huntington's disease and Lou Gehrig's disease combined. Ive lived with primary torsion dystonia since childhood, so this discovery hits very close to home for my family and for so many others in the community.

Bonnie Strauss, President and Founder of the Bachmann-Strauss Dystonia & Parkinson Foundation commented, There is no definitive test or diagnosis for dystonia, nor is there a known cure. While hundreds of thousands of adults and children suffer from symptoms related to the disease, a large majority of patients never receive a proper prognosis. This exciting new research may provide an opportunity for a definitive genetic test to aid diagnosis and treatment.

Study authors include scientists from Beth Israel Medical Center; Albert Einstein College of Medicine; Scripps Research Institute; University of California, San Francisco; Emory University School of Medicine; Toronto Western Hospital; Jefferson Hospital for Neuroscience; Massachusetts General Hospital, and Institute National de la Sant et la Recherche Mdicale (INSERM).

About The Mount Sinai Medical Center

Go here to see the original:
Mount Sinai Scientists Discover New Genetic Basis for Dystonia, a Debilitating Movement Disorder Impacting 500,000 ...

Comments are closed.